Rising Regulatory Hurdles Will Undercut Pharmaceutical Profits Despite Pipeline Hope

Published
08 Apr 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
US$24.00
4.8% overvalued intrinsic discount
09 Aug
US$25.14
Loading
1Y
-12.7%
7D
2.3%

Author's Valuation

US$24.0

4.8% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on30 Apr 25
Fair value Increased 0.63%

AnalystLowTarget has increased revenue growth from -3.2% to -2.9%.

Shared on23 Apr 25
Fair value Decreased 6.73%

AnalystLowTarget has increased revenue growth from -2.9% to -3.2%.

Shared on16 Apr 25
Fair value Decreased 1.77%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on10 Apr 25
Fair value Increased 13%

AnalystLowTarget has increased revenue growth from -2.0% to -2.9%.